Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNA2 | P20248 | 3/20 | 0.42 |
| ▸ | CDK2 | P24941 | 3/20 | 0.42 |
| ▸ | CCNA1 | P78396 | 2/20 | 0.42 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.38 |
| ▸ | RPS6KB1 | P23443 | 7/20 | 0.35 |
| ▸ | AKT1 | P31749 | 5/20 | 0.35 |
| ▸ | GDA | Q9Y2T3 | 1/20 | 0.34 |
| ▸ | DYRK1A | Q13627 | 3/20 | 0.33 |
| ▸ | DYRK1B | Q9Y463 | 3/20 | 0.33 |
| ▸ | CLK2 | P49760 | 2/20 | 0.33 |
| ▸ | CLK3 | P49761 | 1/20 | 0.33 |
| ▸ | CDK9 | P50750 | 2/20 | 0.32 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.32 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.32 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | MC4R | P32245 | 1/20 | 0.32 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.32 |
| ▸ | MC3R | P41968 | 1/20 | 0.32 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16516909 | 0.84 | HCAR2 (0.36) | CCNA2CDK2RPS6KB1AKT1DYRK1A | |
| SCHEMBL1689037 | 0.79 | CYP1A2 (0.36) | CCNA2CDK2DYRK1ADYRK1BCLK2 | |
| SCHEMBL5616254 | 0.75 | GABRG2 (0.38) | NTRK1 | |
| SCHEMBL5084936 | 0.72 | CCNA2 (0.39) | CCNA2CDK2CCNA1PDPK1RPS6KB1 | |
| SCHEMBL1384474 | 0.72 | GSK3A (0.48) | CCNA2CDK2CCNA1DYRK1ACLK2 | |
| SCHEMBL1559614 | 0.72 | CCNA2 (0.52) | CCNA2CDK2CCNA1PDPK1RPS6KB1 | |
| SCHEMBL21806796 | 0.72 | DYRK1A (0.38) | CCNA2CDK2DYRK1ADYRK1BCLK2 | |
| SCHEMBL8328800 | 0.72 | DYRK1A (0.52) | CCNA2CDK2DYRK1ADYRK1BCLK2 | |
| SCHEMBL1689095 | 0.71 | HTT (0.38) | CCNA2CDK2DYRK1ACLK2CLK3 | |
| SCHEMBL8319708 | 0.71 | DYRK1B (0.40) | DYRK1ADYRK1BCLK2CDK9CHEK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3236943-A1 | COMPOSITIONS FOR ILEO-JEJUNAL DRUG DELIVERY | PRINCIPIA BIOPHARMA INC. (US) | 2017-11-01 | — | — | EP | claimed |
| EP-3143021-A1 | PYRAZOLOPYRIDINES AND PYRAZOLOPYRIMIDINES | Pfizer Inc (US) | 2017-03-22 | — | — | EP | claimed |
| WO-2016105582-A1 | COMPOSITIONS FOR ILEO-JEJUNAL DRUG DELIVERY | NUNN PHILIP A (US) | 2016-06-30 | — | — | WO | claimed |
| WO-2015173683-A1 | PYRAZOLOPYRIDINES AND PYRAZOLOPYRIMIDINES | PFIZER INC. (US) | 2015-11-19 | — | — | WO | claimed |
| EP-1807429-A2 | COMPOUNDS AND COMPOSITIONS AS INHIBITORS OF CANNABINOID RECEPTOR 1 ACTIVITY | IRM, LLC (BM) | 2007-07-18 | — | — | EP | claimed |
| WO-2006047516-A2 | COMPOUNDS AND COMPOSITIONS AS INHIBITORS OF CANNABINOID RECEPTOR 1 ACTIVITY | IRM LLC (BM) | 2006-05-04 | — | — | WO | claimed |
| US-20250032623-A1 | HETEROBIFUNCTIONAL COMPOUNDS AND THEIR USE IN TREATING DISEASE | HALDA THERAPEUTICS OPCO, INC. | 2025-01-30 | — | — | US | disclosed |
| EP-3341374-A1 | COMPOUNDS AND COMPOSITIONS USEFUL FOR TREATING DISORDERS RELATED TO NTRK | Blueprint Medicines Corporation (US) | 2018-07-04 | — | — | EP | disclosed |
| EP-3236943-A1 | COMPOSITIONS FOR ILEO-JEJUNAL DRUG DELIVERY | PRINCIPIA BIOPHARMA INC. (US) | 2017-11-01 | — | — | EP | disclosed |
| EP-3233103-A1 | TREATMENT OF PEMPHIGUS | PRINCIPIA BIOPHARMA, INC. (US) | 2017-10-25 | — | — | EP | disclosed |
| EP-3143021-A1 | PYRAZOLOPYRIDINES AND PYRAZOLOPYRIMIDINES | Pfizer Inc (US) | 2017-03-22 | — | — | EP | disclosed |
| WO-2017035354-A1 | COMPOUNDS AND COMPOSITIONS USEFUL FOR TREATING DISORDERS RELATED TO NTRK | BLUEPRINT MEDICINES CORPORATION (US) | 2017-03-02 | — | — | WO | disclosed |
| WO-2016105582-A1 | COMPOSITIONS FOR ILEO-JEJUNAL DRUG DELIVERY | NUNN PHILIP A (US) | 2016-06-30 | — | — | WO | disclosed |
| EP-3036230-A1 | ALKYNYL ALCOHOLS AND METHODS OF USE | F. Hoffmann-La Roche AG (CH) | 2016-06-29 | — | — | EP | disclosed |
| WO-2016100914-A1 | TREATMENT OF PEMPHIGUS | GOURLAY STEVEN (US) | 2016-06-23 | — | — | WO | disclosed |
| WO-2015173683-A1 | PYRAZOLOPYRIDINES AND PYRAZOLOPYRIMIDINES | PFIZER INC. (US) | 2015-11-19 | — | — | WO | disclosed |
| WO-2015025025-A1 | ALKYNYL ALCOHOLS AND METHODS OF USE | F. HOFFMANN-LA ROCHE AG (CH) | 2015-02-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250032623-A1 | HETEROBIFUNCTIONAL COMPOUNDS AND THEIR USE IN TREATING DISEASE | AURKB, CDK9, AURKA | CCNA2 384/4885CDK2 26/4885CCNA1 267/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.